The influence of ART on the treatment of Trichomonas vaginalis among HIV-infected women

Clinical Infectious Diseases

Volumn 59, Issue 6, 2014, Pages 883-887

  Adamski, Alys ^a   Clark, Rebecca A ^b   Mena, Leandro ^c   Henderson, Harold ^c   Levison, Judy ^d   Schmidt, Norine ^a   Gebrekristos, Hirut T ^a   Martin, David H ^b   Kissinger, Patricia ^a  

^a TULANE UNIVERSITY   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antiretroviral; HIV; Metronidazole; Trichomonas vaginalis

Indexed keywords

METRONIDAZOLE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIPROTOZOAL AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; KENYA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUALITY; TREATMENT FAILURE; TREATMENT OUTCOME; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; CD4 LYMPHOCYTE COUNT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; MALE; MIXED INFECTION; PARASITOLOGY; RISK FACTOR; TRICHOMONAS VAGINITIS; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIPROTOZOAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COINFECTION; FEMALE; HIV INFECTIONS; HUMANS; MALE; RISK FACTORS; TREATMENT OUTCOME; TRICHOMONAS VAGINALIS; TRICHOMONAS VAGINITIS; VIRAL LOAD;

EID: 84907384916     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu401     Document Type: Article

References (25)

1. World Health Organization. Prevalence and incidence of selected sexually transmitted infections. Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis and Trichomonas vaginalis. Methods and results used by WHO to generate 2005 estimates. World Health Organization: Geneva, Switzerland, 2011.
2. Magnus M, Clark R, Myers L, Farley T, Kissinger PJ. Trichomonas vaginalis among HIV-infected women: Are immune status or protease inhibitor use associated with subsequent T. vaginalis positivity? Sex Transm Dis 2003; 30:839-43.
3. Clark RA, Theall KP, Amedee AM, Kissinger PJ. Frequent douching and clinical outcomes among HIV-infected women. Sex Transm Dis 2007; 34:985-90.
4. Kissinger PJ, Dumestre J, Clark RA, et al. Vaginal swabs versus lavage for detection of Trichomonas vaginalis and bacterial vaginosis among HIV-positive women. Sex Transm Dis 2005; 32:227-30.
5. Seth P, Wingood GM, Diclemente RJ. Exposure to alcohol problems and its association with sexual behaviour and biologically confirmed Trichomonas vaginalis among women living with HIV. Sex Transm Infect 2008; 84:390-2.
6. Bersoff-Matcha SJ, Horgan MM, Fraser VJ, Mundy LM, Stoner BP. Sexually transmitted disease acquisition among women infected with human immunodeficiency virus type 1. J Infect Dis 1998; 178:1174-7.
7. Hobbs MM, Sena A, Swygard H, et al. Trichomonas vaginalis and trichomoniasis. In: Holmes KK, Stamm WE, Piot P, et al. ed. Sexually transmitted diseases. 4th ed. New York: McGraw-Hill, 2008.
8. Kissinger P, Adamski A. Trichomoniasis and HIV interactions: A review. Sex Transm Infect 2013; 89:426-33.
9. Sorvillo F, Kerndt P. Trichomonas vaginalis and amplification of HIV-1 transmission. Lancet 1998; 351:213-4.
10. Sorvillo F, Smith L, Kerndt P, Ash L. Trichomonas vaginalis, HIV, and African-Americans. Emerg Infect Dis 2001; 7:927-32.
11. Schmid G, Narcisi E, Mosure D, Secor WE, Higgins J, Moreno H. Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic. J Reprod Med 2001; 46:545-9.
12. Kirkcaldy RD, Augostini P, Asbel LE, et al. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD surveillance network, 2009-2010. Emerg Infect Dis 2012; 18:939-43.
13. Niccolai LM, Kopicko JJ, Kassie A, Petros H, Clark RA, Kissinger P. Incidence and predictors of reinfection with Trichomonas vaginalis in HIV-infected women. Sex Transm Dis 2000; 27:284-8.
14. Kissinger P, Secor WE, Leichliter JS, et al. Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women. Clin Infect Dis 2008; 46:994-9.
15. Kissinger P, Mena L, Levison J, et al. A randomized treatment trial: Single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr 2010; 55:565-71.
16. Moodley P, Connolly C, Sturm AW. Interrelationships among human immunodeficiency virus type 1 infection, bacterial vaginosis, trichomoniasis, and the presence of yeasts. J Infect Dis 2002; 185:69-73.
17. Gatski M, Martin DH, Levison J, et al. The influence of bacterial vaginosis on the response to Trichomonas vaginalis treatment among HIV-infected women. Sex Transm Infect 2011; 87:205-8.
18. Balkus JE, Richardson BA, Mochache V, et al. A prospective cohort study comparing the effect of single-dose 2 g metronidazole on Trichomonas vaginalis infection in HIV-seropositive versus HIV-seronegative women. Sex Transm Dis 2013; 40:499-505.
19. Swartzendruber A, Sales JM, Brown JL, Diclemente RJ, Rose ES. Correlates of incident Trichomonas vaginalis infections among African American female adolescents. Sex Transm Dis 2014; 41:240-5.
20. Karamanakos PN, Pappas P, Boumba VA, et al. Pharmaceutical agents known to produce disulfiram-like reaction: Effects on hepatic ethanol metabolism and brain monoamines. Int J Toxicol 2007; 26:423-32.
21. Derbent AU, Ulukanligil M, Keskin EA, Soylu G, Kafali H. Does vaginal irrigation with saline solution in women with infectious vaginitis contribute to the clinical and microbiological results of antibiotic therapy? Gynecol Obstet Invest 2012; 73:195-200.
22. Gatski M, Mena L, Levison J, et al. Patient-delivered partner treatment and Trichomonas vaginalis repeat infection among human immunodeficiency virus-infected women. Sex Transm Dis 2010; 37:502-5.
23. Gatski M, Kissinger P. Observation of probable persistent, undetected Trichomonas vaginalis infection among HIV-positive women. Clin Infect Dis 2010; 51:114-5.
24. Peterman TA, Tian LH, Metcalf CA, et al. Persistent, undetected Trichomonas vaginalis infections? Clin Infect Dis 2009; 48:259-60.
25. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991; 29:297-301.